These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35984649)

  • 61. The role of 5'nucleotidase in therapy-resistance of childhood leukemia.
    Pieters R; Veerman AJ
    Med Hypotheses; 1988 Sep; 27(1):77-80. PubMed ID: 2849709
    [TBL] [Abstract][Full Text] [Related]  

  • 62.
    Fan POL; Leung KT; Chan KYY; Leung AWK; Lam GKS; Chow TTW; Cheng FWT; Yuen LYP; Moriyama T; Yang JJ; Li CK
    Pediatr Hematol Oncol; 2022 Apr; 39(3):254-266. PubMed ID: 34665987
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular mechanism of c-Myc and PRPS1/2 against thiopurine resistance in Burkitt's lymphoma.
    Li T; Song L; Zhang Y; Han Y; Zhan Z; Xv Z; Li Y; Tang Y; Yang Y; Wang S; Li S; Zheng L; Li Y; Gao Y
    J Cell Mol Med; 2020 Jun; 24(12):6704-6715. PubMed ID: 32391636
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
    Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
    Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants?
    Zhou H; Li L; Yang P; Yang L; Zheng JE; Zhou Y; Han Y
    BMC Cancer; 2018 May; 18(1):516. PubMed ID: 29720126
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of
    Ruel NM; Nguyen KH; Kim CS; Andrade LPS; Hammond JR
    J Pharmacol Exp Ther; 2022 Sep; 382(3):335-345. PubMed ID: 35798387
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.
    Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM
    Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Schizophrenia risk proteins ZNF804A and NT5C2 interact in cortical neurons.
    Aabdien A; Sichlinger L; Borgel Z; Jones MR; Waston IA; Gatford NJF; Raval P; Tanangonan L; Powell TR; Duarte RRR; Srivastava DP
    Eur J Neurosci; 2024 Apr; 59(8):2102-2117. PubMed ID: 38279611
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
    Hayder S; Björk O; Lafolie P
    Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.
    Adam de Beaumais T; Jacqz-Aigrain E
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1233-42. PubMed ID: 22421815
    [TBL] [Abstract][Full Text] [Related]  

  • 72. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
    Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
    Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.
    Zhou Y; Wang L; Zhai XY; Wen L; Tang F; Yang F; Liu XT; Dong L; Zhi LJ; Shi HY; Hao GX; Zheng Y; Jacqz-Aigrain E; Wang TY; Zhao W
    Br J Clin Pharmacol; 2020 Aug; 86(8):1519-1527. PubMed ID: 32077136
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia.
    Lane DM; George SL; Komp D; Lonsdale D; Pullen J; Ragab A; Starling KA
    Cancer; 1977 Nov; 40(5):2005-9. PubMed ID: 336174
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population.
    Ramalingam R; Kaur H; Scott JX; Sneha LM; Arun Kumar GP; Srinivasan A; Paul SF
    Pharmacogenomics; 2021 May; 22(7):401-411. PubMed ID: 33876659
    [No Abstract]   [Full Text] [Related]  

  • 76. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
    Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
    Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.
    Yang JJ; Landier W; Yang W; Liu C; Hageman L; Cheng C; Pei D; Chen Y; Crews KR; Kornegay N; Wong FL; Evans WE; Pui CH; Bhatia S; Relling MV
    J Clin Oncol; 2015 Apr; 33(11):1235-42. PubMed ID: 25624441
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MSH6 haploinsufficiency at relapse contributes to the development of thiopurine resistance in pediatric B-lymphoblastic leukemia.
    Evensen NA; Madhusoodhan PP; Meyer J; Saliba J; Chowdhury A; Araten DJ; Nersting J; Bhatla T; Vincent TL; Teachey D; Hunger SP; Yang J; Schmiegelow K; Carroll WL
    Haematologica; 2018 May; 103(5):830-839. PubMed ID: 29449434
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Preclinical evaluation of
    Nishii R; Moriyama T; Janke LJ; Yang W; Suiter CC; Lin TN; Li L; Kihira K; Toyoda H; Hofmann U; Schwab M; Takagi M; Morio T; Manabe A; Kham S; Jiang N; Rabin KR; Kato M; Koh K; Yeoh AE; Hori H; Yang JJ
    Blood; 2018 May; 131(22):2466-2474. PubMed ID: 29572377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.